The FDA is in chaos. But it's not just about the recent leadership shake-up. A new voucher program is causing concern. It seems to be turning drug approvals into a political bargaining chip. The program aims to speed up drug reviews. But the criteria are vague. It's up to the FDA Commissioner to decide who gets the fast track. This has led to some companies getting ...
Over the past decade, China has been fine-tuning how it approves new traditional Chinese medicines (TCMs). The goal? To make the process better suit the unique nature of these treatments. This effort has led to some interesting changes in what counts as solid evidence for approval. Before the reform, the process was quite different. The focus was heavily on clinical...
Drugs that show potential in treating serious illnesses get the green light from Health Canada. However, there is a catch. Companies must promise to run more tests. These tests confirm if the drugs are as effective as initially thought. This process is not always speedy. It can take a while for these extra studies to finish. The time it takes varies greatly. Some stu...